IP Library Granted Patent US 10,322,085
Granted Patent B2
US 10,322,085 · App. 16/189,767 · Granted Jun 18, 2019

Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,085
App. No.
16/189,767
Granted
Jun 18, 2019
Kind
B2
Abstract

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Claims (31)

1. A foamable composition comprising a carrier and a liquefied or compressed gas propellant, wherein the carrier comprising:

(a) about 15% by weight of the carrier of azelaic acid;

(b) about 2% to about 50% by weight of the carrier of a hydrophobic solvent;

(c) a polar solvent;

(d) a surface-active agent;

(e) a polymeric agent; and

(f) water; and

wherein the surface-active agent comprises a combination of at least two surface-active agents and wherein there is a difference of about 4 or more units between the HLB values of the at least two surface-active agents;

wherein combined amount of the polymeric agent and the surface-active agent is about 0.05% to about 10% by weight of the carrier; and

wherein the liquefied or compressed gas propellant is present at about 3% to about 25% by weight of the composition.

2. The foamable composition of claim 1 , wherein the hydrophobic solvent comprises caprylic/capric triglyceride.

3. The foamable composition of claim 2 , wherein caprylic/capric triglyceride is present at about 11% by weight of the carrier.

4. The foamable composition of claim 1 , wherein the polar solvent comprises dimethyl isosorbide.

5. The foamable composition of claim 4 , wherein dimethyl isosorbide is present at about 5% by weight of the carrier.

6. The foamable composition of claim 4 , wherein the polar solvent further comprises propylene glycol.

7. The foamable composition of claim 1 , wherein the combination comprises at least one non-ionic surface-active agent having an HLB value of less than 9.

8. The foamable composition of claim 7 , wherein the at least one non-ionic surface-active agent comprises glyceryl stearate.

9. The foamable composition of claim 1 , wherein the combination comprises at least one non-ionic surface-active agent having an HLB value of more than 9.

10. The foamable composition of claim 9 , wherein the at least one non-ionic surface-active agent having an HLB value of more than 9 comprises PEG-40 stearate and/or Polysorbate 80.

11. The foamable composition of claim 1 , wherein the combination comprises at least one ionic surface-active agent.

12. The foamable composition of claim 1 , wherein the polymeric agent is present at about 0.01% to about 5% by weight of the carrier.

13. The foamable composition of claim 1 , wherein the polymeric agent comprises a naturally-occurring polymeric agent and/or a semi-synthetic polymeric agent.

14. The foamable composition of claim 13 , wherein the naturally-occurring polymeric agent comprises xanthan gum.

15. The foamable composition of claim 13 , wherein the semi-synthetic polymeric agent comprises methylcellulose.

16. The foamable composition of claim 11 , wherein the foamable composition further comprises a foam adjuvant.

17. The foamable composition of claim 16 , wherein the foam adjuvant comprises a fatty alcohol having 15 or more carbons in its carbon chain and/or a fatty acid having 16 or more carbons in its carbon chain.

18. The foamable composition of claim 17 , wherein the fatty alcohol comprises cetostearyl alcohol.

19. The foamable composition of claim 1 , wherein the foamable composition comprises less than about 5% by weight of the carrier of a short-chain alcohol.

20. The foamable composition of claim 1 , wherein the foamble composition further comprises an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a cleanser, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, a fragrant, a hair conditioner, a humectant, a pearlescent acid, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a protectant, a skin penetrating enhancer, a softener, a solubilizer, a sunscreen, a sun blocking agent, a sunless tanning agent, a viscosity modifier, and/or a vitamin.

21. The foamable composition of claim 1 , the pH of the foamable composition is in the range from about 4.0 to about 6.0.

22. The foamable composition of claim 1 , wherein the foamable composition has a shelf-life of at least one year at ambient temperature.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Apr 17, 2019
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS, LTD.
Reel/Frame 049998/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: TAMARKIN, DOV; FRIEDMAN, DORON; BERMAN, TAL; ZIV, ENBAL; SCHUZ, DAVID
To: FOAMIX LTD.
Reel/Frame 048911/0020 →